Launch of new disinfectant
A new disinfectant based on a safer, more efficient and environmentally friendly way of using glutaraldehyde is being launched onto the world market by GX Laboratories.
The range of GX+ products are formulated using the active ingredient G-cide (Glutaral C11-C15 Pareth 9), a new complex which is able to kill 99.9% of bacteria, viruses, fungi and spores in a much shorter time than existing products and at similar concentrations. The G-cide complex was created by South African scientist Toni Martin. She used the chemical glutaraldehyde and stabilised it by complexing it with a large molecular non-ionic surfactant. In doing so, Martin eliminated many of the safety issues surrounding glutaraldehyde such as skin irritation, corrosion, sensitisation and potential respiratory problems. Glutaraldehyde at near neutral pH is stable for only a limited period of time (14-28 days), whereas the G-cide complex is also near neutral pH but can be safely stored for at least 12 months without reducing its efficacy. GX Laboratories, which owns the worldwide rights to manufacture, distribute and promote products containing G-cide, has established a strategic alliance with Dow Biocides for the supply of glutaraldehyde. The disinfectants have applications in the agricultural and livestock sectors, helping to prevent the spread of contact transmitted diseases such as foot and mouth and avian influenza. They are also beneficial to the food and transport industries, as well as having the potential to significantly reduce a majority of hospital acquired infections. The first range of GX+ products to become available will be hand sanitisers, for use by medical staff. The antimicrobial hand sanitiser, hand soap and moisturising creams are water based, non-irritant and will not dry out the skin. The quick drying and non-greasy GX+ hand product range is also effective against the most serious pathogens, and as a contact disinfectant it has a residual killing power that will help stop the transition of infection from patient to patient.